Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 20 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Medicine

Real-World Treatment Outcomes and Prognostic Factors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer: A Single-Center Study from a High-Volume Tertiary Chest Hospital

  • Abdülkadir Koçanoğlu1
  • Oktay Ünsal1
  • Fatih Kuş1
  • Nesrin Gürçay2
  • Esra Zeynelgil3
  • Yakup Düzköprü4
  • Serdar Karakaya1
4 affiliations
  1. 1Medical Oncology, Ankara Atatürk Sanatorium Training and Research Hospital, Ankara 06110, Türkiye
  2. 2Department of Pathology, Ankara Atatürk Sanatorium Training and Research Hospital, Ankara 06110, Türkiye
  3. 3Medical Oncology, Ankara Etlik City Hospital, Ankara 06010, Türkiye
  4. 4Medical Oncology, Aksaray Training and Research Hospital, Aksaray 68100, Türkiye
Open at sourceDOICite

Abstract

Background/Objectives: Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is a distinct molecular subgroup responsive to EGFR tyrosine kinase inhibitors (TKIs). This study evaluated real-world treatment outcomes and prognostic factors in patients with EGFR-mutated metastatic NSCLC. Methods: This retrospective study included 124 patients treated with first-line EGFR-TKIs between January 2017 and 30 August 2025 at a tertiary center. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and prognostic factors were assessed using Cox proportional hazards models. Results: The median age was 66 years, and 63.7% of patients were female. The most common mutation was exon 19 deletion (65.3%). Median OS for the entire cohort was 31.7 months, and median PFS was 16.3 months. In multivariate analysis, Eastern Cooperative Oncology Group performance status (ECOG PS), histopathological subtype, uncommon EGFR mutations, and bone metastasis were statistically significantly associated with OS in multivariable Cox regression analysis. Among patients receiving second-line treatment, median PFS was 16.7 months with osimertinib and 4.1 months with platinum-based chemotherapy; these nonrandomized treatment-specific outcomes were considered descriptive. Conclusions: In conclusion, the survival outcomes observed in our cohort were generally consistent with previously published real-world data in EGFR-mutant metastatic NSCLC. ECOG performance status and bone metastasis were significantly associated with OS, while associations involving histopathological subtype and uncommon EGFR mutations should be considered exploratory given the small subgroup sizes and limited statistical power. These findings provide real-world evidence on treatment patterns and survival outcomes among patients with EGFR-mutant metastatic NSCLC in Türkiye.

Related

  1. Treatment patterns and outcomes of pediatric rhabdomyosarcoma in a resource-limited setting: A retrospective study from a tertiary hospital in Ethiopia
    S. W. Semayneh, B. T. Liyewu, K. G. Yohannes +6
    medRxivPreprintCC BYFull textOncologymedRxiv
  2. Comparing Surgical Outcomes of Laparoscopic Myomectomy Versus Laparotomy at a Specialized Tertiary Hospital for Women’s Health: A Retrospective Study
    Hala A Bokhari, Maysoon Adham, Maha Alruwaythi +4
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Clinical profile, risk factors and in-hospital outcomes of ST-segment elevation myocardial infarction in young versus older adults: a 5-year retrospective cohort study at a tertiary care centre in Riyadh, Saudi Arabia.
    Faisal Alhusain, Fatimah Alsumari, Renad Almasari +5
    BMJ openPeer-reviewedCC BY-NCFull textCardiovascular medicineEurope PMCCrossref
  4. Glycaemic outcomes of three months of continuous glucose monitoring in children, adolescents and young adults with type 1 diabetes at a Kenyan tertiary hospital: a single-arm prospective study.
    L. W. Mungai, P. Amolo, A. K. Karume +7
    medRxivPreprintAll rights reservedFull textEndocrinology & metabolismmedRxiv
  5. Receptor Status Changes, HER2-Low Discordance, and TNBC Transformation in Metastatic Breast Cancer: Prognostic Significance and Impact on Survival Outcomes
    Ayşe Nuransoy Cengiz, Muhammet Cengiz, Oktay Bozkurt +7
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kocanoglu2026realworld,
  title = {{Real-World Treatment Outcomes and Prognostic Factors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer: A Single-Center Study from a High-Volume Tertiary Chest Hospital}},
  author = {Abdülkadir Koçanoğlu and Oktay Ünsal and Fatih Kuş and Nesrin Gürçay and Esra Zeynelgil and Yakup Düzköprü and Serdar Karakaya},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  month = oct,
  doi = {10.3390/jcm15218206},
  url = {https://www.mdpi.com/2077-0383/15/21/8206},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Real-World Treatment Outcomes and Prognostic Factors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer: A Single-Center Study from a High-Volume Tertiary Chest Hospital
AU  - Abdülkadir Koçanoğlu
AU  - Oktay Ünsal
AU  - Fatih Kuş
AU  - Nesrin Gürçay
AU  - Esra Zeynelgil
AU  - Yakup Düzköprü
AU  - Serdar Karakaya
PY  - 2026
DA  - 2026/10/22
JO  - Journal of Clinical Medicine
DO  - 10.3390/jcm15218206
UR  - https://www.mdpi.com/2077-0383/15/21/8206
AB  - Background/Objectives: Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is a distinct molecular subgroup responsive to EGFR tyrosine kinase inhibitors (TKIs). This study evaluated real-world treatment outcomes and prognostic factors in patients with EGFR-mutated metastatic NSCLC. Methods: This retrospective study included 124 patients treated with first-line EGFR-TKIs between January 2017 and 30 August 2025 at a tertiary center. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and prognostic factors were assessed using Cox proportional hazards models. Results: The median age was 66 years, and 63.7% of patients were female. The most common mutation was exon 19 deletion (65.3%). Median OS for the entire cohort was 31.7 months, and median PFS was 16.3 months. In multivariate analysis, Eastern Cooperative Oncology Group performance status (ECOG PS), histopathological subtype, uncommon EGFR mutations, and bone metastasis were statistically significantly associated with OS in multivariable Cox regression analysis. Among patients receiving second-line treatment, median PFS was 16.7 months with osimertinib and 4.1 months with platinum-based chemotherapy; these nonrandomized treatment-specific outcomes were considered descriptive. Conclusions: In conclusion, the survival outcomes observed in our cohort were generally consistent with previously published real-world data in EGFR-mutant metastatic NSCLC. ECOG performance status and bone metastasis were significantly associated with OS, while associations involving histopathological subtype and uncommon EGFR mutations should be considered exploratory given the small subgroup sizes and limited statistical power. These findings provide real-world evidence on treatment patterns and survival outcomes among patients with EGFR-mutant metastatic NSCLC in Türkiye.
SN  - 2077-0383
ER  -